• Explore /
  • Poster
  • / Minimal residual disease by circulating tumor DNA as a biomarker of recurrence free survival in resected high-risk melanoma patients treated with mRNA-4157/V940, a personalized cancer vaccine, and pembrolizumab.

Minimal residual disease by circulating tumor DNA as a biomarker of recurrence free survival in resected high-risk melanoma patients treated with mRNA-4157/V940, a personalized cancer vaccine, and pembrolizumab.

Abstract Poster

Authors

null

Matteo S. Carlino

Sydney Medical School, Faculty of Medicine and Health Sciences, University of Sydney, Camperdown and Melanoma Institute Australia, Sydney, NSW, Australia, and Crown Princess Mary Cancer Centre, Westmead and Blacktown Hospitals, Westmead, Australia

Matteo S. Carlino , Adnan Khattak , Jeffrey S. Weber , Tarek Meniawy , Ryan J. Sullivan , Matthew H. Taylor , Kevin B. Kim , Meredith McKean , Mark B Faries , Charles Lance Cowey , Geoffrey Thomas Gibney , Jason J. Luke , Sajeve Samuel Thomas , Vasudha Sehgal , Igor Feldman , Praveen Aanur , Michelle Brown , Robert S. Meehan , Celine Robert-Tissot , Georgina V. Long

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Annual Meeting

Session Type

Poster Discussion Session

Session Title

Melanoma/Skin Cancers

Track

Melanoma/Skin Cancers

Sub Track

Advanced/Metastatic Disease

Clinical Trial Registration Number

NCT03897881

Citation

J Clin Oncol 41, 2023 (suppl 17; abstr LBA9515)

DOI

10.1200/JCO.2023.41.17_suppl.LBA9515

Abstract #

LBA9515

Poster Bd #

278

Abstract Disclosures

Similar Posters

First Author: Rong Yin

First Author: Yinyin Chang

First Author: Michael Mitchell

First Author: De-Zhen Guo